These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31897805)

  • 21. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
    Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an In Vitro Drug Release Method to Enable In Vitro-In Vivo Correlation of Potassium Chloride Extended-Release Tablets.
    Qiu Y; Zhu DA; Apfelbaum K; Zu H; Xiong H
    Mol Pharm; 2022 Nov; 19(11):4191-4198. PubMed ID: 36049021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing Abuse-Deterrent formulations utilizing Ion-Exchange resin complexation processed via Twin-Screw granulation for improved safety and effectiveness.
    Ram Munnangi S; Narala N; Lakkala P; Kumar Vemula S; Repka M
    Eur J Pharm Biopharm; 2024 Apr; 197():114230. PubMed ID: 38373555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and in vitro evaluation of an abuse-deterrent formulation based on a crosslinked starch derivative.
    Ahmad R; Omidian H
    Int J Pharm; 2019 Oct; 569():118602. PubMed ID: 31394182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties.
    Ong JJ; Awad A; Martorana A; Gaisford S; Stoyanov E; Basit AW; Goyanes A
    Int J Pharm; 2020 Apr; 579():119169. PubMed ID: 32087263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique.
    Singh SK; Srinivasan KK; Gowthamarajan K; Prakash D; Gaikwad NB; Singare DS
    Drug Dev Ind Pharm; 2012 Aug; 38(8):961-70. PubMed ID: 22251080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.
    Simon A; Amaro MI; Healy AM; Cabral LM; de Sousa VP
    AAPS PharmSciTech; 2017 Oct; 18(7):2561-2569. PubMed ID: 28224389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products.
    Rahman Z; Aqueel MS; Korang-Yeboah M; Zidan AS; Chen J; Alayoubi AY; Cruz CN; Ashraf M
    Int J Pharm; 2020 Feb; 575():118909. PubMed ID: 31811923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.
    Rezaei L; Meruva S; Donovan MD
    AAPS PharmSciTech; 2021 Dec; 23(1):38. PubMed ID: 34961912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion.
    Nukala PK; Palekar S; Patki M; Fu Y; Patel K
    Int J Pharm; 2019 Oct; 569():118629. PubMed ID: 31425818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications.
    Hill SW; Varker AS; Karlage K; Myrdal PB
    J Manag Care Pharm; 2009 Apr; 15(3):253-61. PubMed ID: 19326956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation.
    Mendes TC; Simon A; Menezes JCV; Pinto EC; Cabral LM; de Sousa VP
    Chem Pharm Bull (Tokyo); 2019; 67(1):23-31. PubMed ID: 30606948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling and comparison of release profiles: Effect of the dissolution method.
    Cascone S
    Eur J Pharm Sci; 2017 Aug; 106():352-361. PubMed ID: 28627469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended release delivery system of metoprolol succinate using hot-melt extrusion: effect of release modifier on methacrylic acid copolymer.
    Sawant KP; Fule R; Maniruzzaman M; Amin PD
    Drug Deliv Transl Res; 2018 Dec; 8(6):1679-1693. PubMed ID: 29948916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A better dissolution method for ranitidine tablets USP.
    Cappola ML
    Pharm Dev Technol; 2001; 6(1):11-7. PubMed ID: 11247270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.